Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Executive Summary

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

You may also be interested in...



Express Scripts Value-Based Program To Leverage Generic Advair

Pharmacy benefit manager Express Scripts plans to shake up the asthma/pulmonary and multiple sclerosis categories in 2018 with new contracting programs.

Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis

'Perverse incentives' guide US pricing for rheumatoid arthritis drugs, stakeholders say at policy roundtable convened by Institute for Clinical and Economic Review.

Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow

Amgen seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS118785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel